LataMed AI Corp. (OTC: LMED), a digital health and artificial intelligence technology company focused on telehealth infrastructure for emerging markets, announced today that it expects to submit a corporate action request to FINRA seeking approval of a five-for-one forward stock split. The proposed split would proportionally increase the company’s authorized common and preferred stock, including its Series C Voting Preferred Stock, and is intended to support long-term operational scalability and future growth initiatives.
The company stated that the forward stock split is part of its broader strategy to align its capital structure with its ongoing transition into digital healthcare infrastructure and AI-driven telehealth operations. Management emphasized that the corporate action does not involve debt restructuring, recapitalization, or reduction in shareholder ownership percentages. Any fractional shares resulting from the split would be rounded up to the nearest whole share pursuant to board resolutions.
Dr. Kevin Rodan Levy, CEO of LataMed AI, commented: “As we continue advancing our operational and commercialization initiatives throughout Latin America, we believe this proposed forward stock split and proportional capital structure expansion may support broader long-term strategic flexibility, operational scalability, and future growth initiatives as we continue building our healthcare technology platform.”
The announcement follows the company’s recent commencement of initial operational activities for its telehealth platform in Venezuela after receiving regulatory authorization from the Ministerio del Poder Popular para la Salud and Servicio Autonomo de Contraloria Sanitaria (SACS). LataMed AI is building a technology-enabled healthcare ecosystem designed to support remote patient engagement, provider coordination, healthcare analytics, and broader digital healthcare delivery in emerging markets, with an initial focus on Latin America.
The forward stock split remains subject to FINRA review and approval, completion of applicable regulatory processing, and final corporate implementation procedures. The company noted that no assurance can be provided regarding the timing or ultimate effectiveness of the proposed corporate action. Investors are cautioned that the company is a development-stage enterprise and has not generated revenues from its current business operations.
LataMed AI Corp. is positioning itself to participate in the modernization and digital transformation of healthcare delivery systems across emerging markets through telehealth infrastructure development, AI-driven technologies, regulatory progression, and strategic partnerships. For more information, visit https://latamed.ai or review the company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
